4 edition of Molecular and clinical advances in anticancer drug resistance found in the catalog.
Includes bibliographical references and index.
|Statement||edited by Robert F. Ozols.|
|Series||Cancer treatment and research ;, 57, Cancer treatment and research ;, v. 57.|
|Contributions||Ozols, Robert F.|
|LC Classifications||RC271.C5 M644 1991|
|The Physical Object|
|Pagination||xii, 308 p. :|
|Number of Pages||308|
|LC Control Number||91007026|
Improved understanding of the molecular basis of resistance will inevitably lead to the clinical assessment of rational drug combinations in selected patient populations. AbstractCited by: All successful cancer therapies are limited by the development of drug resistance. The increase in the understanding of the molecular and biochemical bases of drug efficacy has also facilitated studies elucidating the mechanism(s) of drug resistance. Experimental approaches that can help predict the eventual clinical drug resistance, coupled with the evolution of systematic genomic Cited by:
The focus of Medicinal Chemistry of Anticancer Drugs is on the mechanism of action of antitumor drugs from the molecular point of view and on the relationship between chemical structure and chemical and biochemical reactivity of antitumor agents, aiming at the rationalization of the action of this type of drug, which would allow the design of Book Edition: 1. Special Issue in International Journal of Molecular Sciences: Advances in the Comprehension of the Molecular Basis of Cancer and New Therapeutic Strategies Special Issue in Cancers: Experimental and Clinical Advances in Counteracting Progression of Solid Cancers.
BetA is being developed by a large network of clinical trial groups with the support of the U.S. National Cancer Institute. This article discusses recent advances in research into anticancer activity of BetA, relevant modes of delivery, and the agent's therapeutic efficacy, mechanism of action, and future perspective as a pipeline anticancer by: Pharmacology on the Academic Oxford University Press website. Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide.
To eliminate the opiate
Summary guide to collections.
Quantitative analysis of the EEG
Teachers Word Lists for Reference (Revised Edition)
Ocean thermal energy conversion, phase I
General education in higher education
Pension simplification and investment rules
Canada and its provinces
Beckerts garden annual
Electromagnetic interference shielding
The purpose of this volume is to describe the new advances, both at the molecular level and in the clinic regarding mechanisms of drug resistance and potential ways this resistance. Although MDR is currently the most understood mechanism of drug resistance, we are uncovering increasing knowledge of alternative molecular and biochemical mechanisms of drug resistance to antimetabolites, cisplatin and alkylating agents and developing new strategies for circumventing such resistance.
It is clear that drug resistance is complex, and many mechanisms exist by which cancer cells. Read "Molecular and Clinical Advances in Anticancer Drug Resistance" by available from Rakuten Kobo. The importance of drug resistance in cancer chemotherapy cannot be over stated.
Thepatients who die every year Brand: Springer US. Over the last 50 years, drug development and clinical trials have resulted in successful complete responses in diseases such as childhood leukemia, testicular cancer and Hodgkin's disease. We are still, however, confronted with overcancer-related deaths per year.
Clearly, the Price: $ Lee "Molecular and Clinical Advances in Anticancer Drug Resistance" por disponible en Rakuten Kobo. The importance of drug resistance in cancer chemotherapy cannot be over stated. Thepatients who die every year Brand: Springer US. Over the last 50 years, drug development and clinical trials have resulted in successful complete responses in diseases such as childhood leukemia, testicular cancer and Hodgkin's disease.
We are still, however, confronted with overcancer-related deaths per by: Molecular and Clinical Advances in Anticancer Drug Resistance. [Robert F Ozols] -- The importance of drug resistance in cancer chemotherapy cannot be over stated.
Thepatients who die every year from cancer in the United States have, in most cases, been treated with. Cancer Treat Res.
; Molecular and clinical advances in anticancer drug resistance. [No authors listed] PMID: [PubMed - indexed for MEDLINE]. This review summarizes the recent knowledge obtained on the molecular mechanisms involved in the intrinsic and acquired resistance of cancer cells to current cancer therapies.
We describe the cascades that are often altered in cancer cells during cancer progression that may contribute in a crucial manner to drug resistance and disease by: Drawing on the fields of authors draw on the fields of medicinal chemistry, pharmacology, biochemistry, cell biology, molecular biology, and clinical medicine, this timely book is extensively referenced and provides a historical background for the development of each class of drugs.2/5(1).
Recent Advances on the Molecular Mechanisms Involved in the Drug Resistance of Cancer Cells and Novel Targeting Therapies M Mimeault, 1, 2 R Hauke, 2, 3 and SK Batra 1, 2, 4 1 Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska, USACited by: The development of resistance is a problem shared by both classical chemotherapy and targeted therapy.
Patients may respond well at first, but relapse is inevitable for many cancer patients, despite many improvements in drugs and their use over the last 40 years.
Resistance to anti-cancer drugs can be acquired by several mechanisms within neoplastic cells, defined as (1) alteration of drug Cited by: Cancer Drug Design and Discovery, Second Edition is an important reference on the underlying principles for the design and subsequent development of new anticancer small molecule agents.
New chapters have been added to this edition on areas of particular interest and therapeutic promise, including cancer genomics and personalized medicine, DNA. Abstract. Poly(ADP-ribose)polymerase 1 (PARP) is a nuclear enzyme involved in DNA repair.
This chapter outlines the discovery of the PARP family and the rationale for the development of PARP inhibitors as a novel class of anticancer agents, with a brief evaluation of the preclinical evidence for chemo-potentiation, radio-potentiation, and also single agent activity in homologous recombination.
Molecular and clinical advances in anticancer drug resistance. Boston: Kluwer Academic Publishers, (OCoLC) Online version: Molecular and clinical advances in anticancer drug resistance.
Boston: Kluwer Academic Publishers, (OCoLC) Material Type: Internet resource: Document Type: Book, Internet Resource: All Authors. Introduction: With the increasing incidence of esophageal cancer, drug resistance is becoming a major obstacle to successful cancer therapy since chemotherapy is regarded as a curative approach to inhibit cancer cell e the great progress in anticancer treatment achieved during the last decades, the mechanisms of multidrug resistance have not been completely by: 7.
Cancer Drug Design and Discovery, Second Edition is an important reference on the underlying principles for the design and subsequent development of new anticancer small molecule agents. New chapters have been added to this edition on areas of particular interest and therapeutic promise, including cancer genomics and personalized medicine, DNA-targeted agents and more.
Review Resistance to anti-cancer drugs can be acquired by several mechanisms within neoplastic cells, defined as (1) alteration of drug targets, (2) expression of drug pumps, (3) expression of.
Chemistry and Pharmacology of Anticancer Drugs is a comprehensive survey of all families of anticancer agents currently in use or in advanced stages of clinical trials, including biologicals.
The book is unique in providing molecular structures for all anticancer drugs, discussing them in terms of history, chemistry, mechanism of action Cited by: Therefore, drug resistance poses a major challenge to breast cancer treatment.
Current developments: Drug resistance in breast cancer is a complex clinical condition originating from a wide range of molecular alterations. The development of endocrine therapy resistance is believed to be associated with many cellular changes, such as ESR1 gene. Clinical Cancer Drugs publishes original research, full-length reviews/ mini reviews, and thematic issues in all core areas of translational and clinical cancer drug research.
The journal publishes pre-clinical and clinical studies on the development of new anti-cancer agents. Clinical studies of new reported anti-cancer drugs include Phase 1–IV clinical trial studies, their designs.Molecular alterations that contribute to intrinsic or acquired treatment resistance include mutation of the drug's molecular target, changes in the way the drug interacts with the tumor, broad cellular changes, and changes in the tumor microenvironment, among others.
To complicate matters, many of these factors can be at play simultaneously in.Request PDF | Advances of Microtubule-Targeting Small Molecular Anticancer Agents from Marine Origin | The unparalleled effectiveness of microtubule-targeting drugs has been validated by the.